EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta‐Analysis of Randomized Trials

Changjiang Deng iD, Yixin Xu iD, Adilai Adilijiang, Zhilong Wang iD, Ying Pan iD, Chao Fan iD, Baichuan Liu iD, Haoxu Lv, Junrui Hou iD, Tingting Wu iD

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/6035178 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 07.07.2026. Verfasst von Changjiang Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China, xjmu.edu.cn. Hauptthemen laut MEDLINE: Heart Failure, Atrial Fibrillation, Anti-Arrhythmia Agents, Heart Rate. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region, Xinjiang Science and Technology, Tian Shan Ying cai Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with HF and AF face high risks of death and HF decompensation, yet the comparative effectiveness of commonly used AF management strategies remains uncertain. This study is aimed at comparing the efficacy and safety of different interventional and medical approaches using NMA of RCTs.

Methods

PubMed, Embase, CENTRAL, Web of Science, and Google Scholar were searched from inception to November 30, 2025, without language restrictions. Parallel‐group RCTs enrolling adults with clinically diagnosed HF and documented AF were eligible if they compared at least two AF management strategies, including CA, AVNA with CRT or RV pacing, MRC, drug‐based rhythm control (rhythm drug), or CON. Primary outcomes were all‐cause mortality and HF hospitalization; secondary outcomes were worsening HF, CV mortality, QoL, and LVEF. Random‐effects NMA was performed in Stata 17.0, reporting ORs and SMDs with 95% CIs; treatments were ranked using SUCRA.

Results

Twenty‐three RCTs (5159 patients) were included. For all‐cause mortality (21 trials; 5095 patients), AVNA_CRT (OR, 0.30; 95% CI, 0.12–0.78) and CA (OR, 0.53; 95% CI, 0.35–0.82) were associated with lower mortality than CON; AVNA_CRT also outperformed MRC (OR, 0.35; 95% CI, 0.15–0.79) and AVNA_RV (OR, 0.49; 95% CI, 0.25–0.96). For HF hospitalization (9 trials; 3491 patients), AVNA_CRT reduced risk compared with AVNA_RV (OR, 0.20; 95% CI, 0.04–0.94). For worsening HF (7 trials; 2542 patients), AVNA_CRT was superior to AVNA_RV (OR, 0.41; 95% CI, 0.20–0.84). CA improved QoL versus AVNA_CRT (SMD, −0.94; 95% CI, −1.83 to −0.05) and MRC (SMD, −0.73; 95% CI, −1.22 to −0.24), and improved LVEF versus MRC (SMD, 1.49; 95% CI, 0.57–2.41). No between‐strategy differences were clearly demonstrated for CV mortality.

Conclusion

In RCT evidence for HF with AF, AVNA_CRT and CA were associated with more favorable prognostic outcomes, and CA provided more consistent improvements in QoL and LVEF. When AVNA is selected, CRT should be preferred over RV pacing. Strategy choice should be individualized to clinical goals, patient phenotype, and procedural feasibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureAtrial FibrillationAnti-Arrhythmia AgentsHeart RateCatheter AblationCardiac Resynchronization TherapyElectric CountershockHumansRandomized Controlled Trials as TopicTreatment OutcomeRisk FactorsFemaleMaleAgedMiddle AgedRecovery of FunctionHospitalizationRisk AssessmentTime FactorsVentricular Function, Left

Stichwörter der Autor:innen

atrial fibrillationatrioventricular node ablationcardiac resynchronization therapycatheter ablationheart failurenetwork meta-analysis

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China, xjmu.edu.cn.
  • Department of Cardiology, Southwest Hospital of AMU, Chongqing, Chongqing, China.
  • Department of Pathophysiology, Xinjiang Medical University College of Basic Medicine, Urumqi, Xinjiang, China.

ORCID-Profile: Changjiang Deng, Yixin Xu, Zhilong Wang, Ying Pan, Chao Fan, Baichuan Liu, Junrui Hou, Tingting Wu

Förderung

  • Natural Science Foundation of Xinjiang Uygur Autonomous Region
  • Xinjiang Science and Technology, Tian Shan Ying cai Project

Zitieren

APA

Deng, C., Xu, Y., Adilijiang, A., Wang, Z., Pan, Y., Fan, C., Liu, B., Lv, H., Hou, J., & Wu, T. (2026). Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta‐Analysis of Randomized Trials. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/6035178

Vancouver

Deng C, Xu Y, Adilijiang A, Wang Z, Pan Y, Fan C, et al. Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta‐Analysis of Randomized Trials. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/6035178

BibTeX
@article{Deng2026,
  author = {Deng, Changjiang and Xu, Yixin and Adilijiang, Adilai and Wang, Zhilong and Pan, Ying and Fan, Chao and Liu, Baichuan and Lv, Haoxu and Hou, Junrui and Wu, Tingting},
  title = {Comparative Effectiveness and Safety of Interventions for Atrial Fibrillation in Heart Failure: A Network Meta‐Analysis of Randomized Trials},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/6035178}
}
Kostenlos starten →